Serum Triglyceride and Apolipoprotein A1 as Biomarkers for Extranodal Natural Killer/T cell Lymphoma (ENKTL): A Multicenter Study

Background: Although clinical outcome of extranodal NK/T cell lymphoma (ENKTL) has been improved recently, some patients resistant to Asp-based chemotherapy suffered poorer survival. Therefore, reliable and convenient biomarkers become more important. Methods: We retrospectively analyzed 1017 ENKTL with available data between December 2003 August 2021. Demographics serum lipid 500 healthy controls were reviewed. The median values at baseline selected as the cutoff for lipid. Results: levels high density lipoprotein cholesterol (HDL-C), low (LDL-C) apolipoprotein A1 (ApoA1) lower, while triglyceride (TG) was higher in than those age- gender-matched (all p < 0.001). Besides conventional predictive factors, TG (PFS: = 0.017; OS: 0.018) ApoA1 0.007; 0.002) identified independent prognostic factors. Among (or ApoA1) baseline, who exhibited objective responses had a significant decrease increase) after treatment 0.001) (Figure A-B). However, no change or observed without satisfactory response. Compared levels, further increased decreased first-line associated significantly shorter PFS OS C-D). developed validated pre-treatment nomogram containing post-treatment best response E-F). PINK, post-nomogram model proved possess power survival concordance index area under curve (AUC) lower integrated Brier score (IBS) 5-year OS. Subgroup analysis showed that Asp-containing regimens benefits among LDL-C HDL-C Furthermore, comprehensive transcriptome provided evidence intratumoral metabolic disorders dysregulated classical tumor-related signaling pathways, including NOTCH MAPK, G-H) Conclusion: This study suggests is accompanied by dyslipidemia. Baseline trends could contribute risk stratification, disease status monitoring prediction. Patients dyslipidemia also have pathway. Encore Abstract - previously submitted EHA 2023 research funded by: grants from National Key Research Development Program (2022YFC2502602), Natural Science Foundation China (82230001 82270199), Sun Yat-Sen University Clinical 5010 (2020009), Special Support Yat-sen Cancer Center (PT19020401), Oncology Chinese Society (Y-XD2019-124 Y-SY2021ZD-0110). Keyword: Extranodal non-Hodgkin No conflicts interests pertinent abstract.